Filter
Sort by
View
21 case(s) found.

Easier Together: Zirq Solutions’ Ecosystem Approach to Recycling Insulin Pens

By  Clara Carrera,  Michael Olenick,  Luk Van Wassenhove,  Atalay Atasu
Add to cart new
The case describes how the Danish company Zirq Solutions, a subsidiary of Norwegian NG Group, brought circular economy thinking to the pharmaceutical industry.

    Published 05 Mar 2024

    Reference 6834

    Length 10 page(s)

    Topic Responsibility

    Region Europe

    Industry Pharmaceuticals,  Renewables & Environment

    View case

    Easier Together: Zirq Solutions’ Ecosystem Approach to Recycling Insulin Pens

    By  Clara Carrera,  Michael Olenick,  Luk Van Wassenhove,  Atalay Atasu
    Add to cart new
    The case describes how the Danish company Zirq Solutions, a subsidiary of Norwegian NG Group, brought circular economy thinking to the pharmaceutical industry.
      View case

      Octapharma (A): Crisis and Leadership

      By  Charles Galunic,  Philippe Ombregt
      Add to cart
      Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.

        Published 27 Jan 2014

        Reference 6031

        Length 11 page(s)

        Topic Leadership & Organisations

        Region Europe

        Industry Pharmaceuticals

        View case

        Octapharma (A): Crisis and Leadership

        By  Charles Galunic,  Philippe Ombregt
        Add to cart
        Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.
          View case

          Octapharma (B): Crisis and Leadership

          By  Charles Galunic,  Philippe Ombregt
          Add to cart
          Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.

            Published 27 Jan 2014

            Reference 6031

            Length 6 page(s)

            Topic Leadership & Organisations

            Region Europe

            Industry Pharmaceuticals

            View case

            Octapharma (B): Crisis and Leadership

            By  Charles Galunic,  Philippe Ombregt
            Add to cart
            Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.
              View case

              Going Green: The Pfizer Freiburg Energy Initiative (A)

              By  Sam Aflaki,  Paul Kleindorfer
              Add to cart
              This case describes the successful implementation of sustainable operations at Pfizer's Freiburg production facility in Germany. It charts the planning and execution of an ambitious portfolio of projects directed toward energy efficiency, with significant financial, social and environmental impacts.

                Published 25 Mar 2010

                Reference 5680

                Length 17 page(s)

                Topic Operations

                Region Europe

                Industry Pharmaceuticals

                View case

                Going Green: The Pfizer Freiburg Energy Initiative (A)

                By  Sam Aflaki,  Paul Kleindorfer
                Add to cart
                This case describes the successful implementation of sustainable operations at Pfizer's Freiburg production facility in Germany. It charts the planning and execution of an ambitious portfolio of projects directed toward energy efficiency, with significant financial, social and environmental impacts.
                  View case

                  Pfizer and the Distribution of Pharmaceuticals in Europe in 2009

                  By  Karel Cool,  Peter Zemsky,  Charlotte Butler
                  Add to cart
                  Faced with increasing parallel imports, Pfizer in Europe decides to change its drug distribution strategy. It introduces a 'Direct to Pharmacy' scheme whereby distributors become mere logistics companies. Pfizer also introduces 'dual pricing' to force wholesalers to sell the drugs in the targeted country.

                    Published 23 Feb 2011

                    Reference 5679

                    Length 31 page(s)

                    Topic Strategy

                    Region Europe

                    Industry Pharmaceuticals

                    View case

                    Pfizer and the Distribution of Pharmaceuticals in Europe in 2009

                    By  Karel Cool,  Peter Zemsky,  Charlotte Butler
                    Add to cart
                    Faced with increasing parallel imports, Pfizer in Europe decides to change its drug distribution strategy. It introduces a 'Direct to Pharmacy' scheme whereby distributors become mere logistics companies. Pfizer also introduces 'dual pricing' to force wholesalers to sell the drugs in the targeted country.
                      View case

                      Amgen Europe in the Renal Anaemia Treatment Market

                      By  Reinhard Angelmar,  Olivier Baron,  Elizabeth Chen,  Gaurav Batti
                      Add to cart
                      Amgen Europe has launched Aranesp, a second-generation EPO product in a market dominated by Johnson & Johnson's pioneering Eprex (US name Procrit), followed by NeoRecormon from Roche. One year after the launch, the sales and market share of Aranesp are below target.

                        Published 04 Jan 2007

                        Reference 5410

                        Length 19 page(s)

                        Topic Marketing

                        Region Europe

                        Industry Pharmaceuticals

                        View case

                        Amgen Europe in the Renal Anaemia Treatment Market

                        By  Reinhard Angelmar,  Olivier Baron,  Elizabeth Chen,  Gaurav Batti
                        Add to cart
                        Amgen Europe has launched Aranesp, a second-generation EPO product in a market dominated by Johnson & Johnson's pioneering Eprex (US name Procrit), followed by NeoRecormon from Roche. One year after the launch, the sales and market share of Aranesp are below target.
                          View case

                          NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK

                          By  Reinhard Angelmar,  Andrea Bieser
                          Add to cart
                          NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient €10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.

                            Published 07 Jan 2006

                            Reference 5381

                            Length 31 page(s)

                            Topic Marketing

                            Region Europe

                            Industry Pharmaceuticals

                            View case

                            NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK

                            By  Reinhard Angelmar,  Andrea Bieser
                            Add to cart
                            NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient €10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.
                              View case

                              Customer Relationship Management at Organon France

                              By  Reinhard Angelmar
                              Add to cart
                              Organon France is the first company to implement a physician-focused customer relationship management (CRM) system. The case describes the different channels through which Organon communicates with physicians, the rationale and metrics for the CRM system, the main steps in CRM implementation, and the issues arising during the actual utilization of the system by the sales force and marketing.

                                Published 31 May 2005

                                Reference 5269

                                Length 22 page(s)

                                Topic Marketing

                                Region Europe

                                Industry Pharmaceuticals

                                View case

                                Customer Relationship Management at Organon France

                                By  Reinhard Angelmar
                                Add to cart
                                Organon France is the first company to implement a physician-focused customer relationship management (CRM) system. The case describes the different channels through which Organon communicates with physicians, the rationale and metrics for the CRM system, the main steps in CRM implementation, and the issues arising during the actual utilization of the system by the sales force and marketing.
                                  View case

                                  Marketing Strategies in the Competition between Branded and Generic Antibiotics (A): Clamoxyl in 1996

                                  By  Pierre Chandon,  Olivier Kovarski,  Jacques Lendrevie,  Marc Vanhuele,  Sarah Spargo
                                  Add to cart
                                  In July 1996, the French social security governmental agency (the CNAM) sent a letter to all doctors urging them to prescribe generic amoxicillin instead of Clamoxyl, SmithKline Beecham’s (SB) blockbuster antibiotic.

                                    Published 01 Jun 2003

                                    Reference 5057

                                    Length 25 page(s)

                                    Topic Marketing

                                    Region Europe

                                    Industry Pharmaceuticals

                                    View case

                                    Marketing Strategies in the Competition between Branded and Generic Antibiotics (A): Clamoxyl in 1996

                                    By  Pierre Chandon,  Olivier Kovarski,  Jacques Lendrevie,  Marc Vanhuele,  Sarah Spargo
                                    Add to cart
                                    In July 1996, the French social security governmental agency (the CNAM) sent a letter to all doctors urging them to prescribe generic amoxicillin instead of Clamoxyl, SmithKline Beecham’s (SB) blockbuster antibiotic.
                                      View case

                                      Marketing Strategies in the Competition between Branded and Generic Antibiotics (B): Augmentin in 2002

                                      By  Pierre Chandon,  Olivier Kovarski,  Jacques Lendrevie,  Marc Vanhuele,  Sarah Spargo
                                      Add to cart
                                      The B case (Augmentin in 2002) shows that GSK (the company formed by the merger of Glaxo Wellcome and SmithKline Beecham) now faces the same options for Augmentin, another blockbuster antibiotic. Should they use the strategy that was so successful for Clamoxyl or have the market conditions changed so much that a whole different approach should followed?

                                        Published 06 Jan 2003

                                        Reference 5057

                                        Length 1 page(s)

                                        Topic Marketing

                                        Region Europe

                                        Industry Pharmaceuticals

                                        View case

                                        Marketing Strategies in the Competition between Branded and Generic Antibiotics (B): Augmentin in 2002

                                        By  Pierre Chandon,  Olivier Kovarski,  Jacques Lendrevie,  Marc Vanhuele,  Sarah Spargo
                                        Add to cart
                                        The B case (Augmentin in 2002) shows that GSK (the company formed by the merger of Glaxo Wellcome and SmithKline Beecham) now faces the same options for Augmentin, another blockbuster antibiotic. Should they use the strategy that was so successful for Clamoxyl or have the market conditions changed so much that a whole different approach should followed?
                                          View case

                                          Lundbeck A/S

                                          By  Lee Remmers
                                          Add to cart
                                          The Lundbeck case study describes the initial public offering (IPO) that the company made in the summer of 1999.

                                            Published 01 Dec 2000

                                            Reference 4927

                                            Length 11 page(s)

                                            Topic Economics & Finance

                                            Region Europe

                                            Industry Pharmaceuticals

                                            View case

                                            Lundbeck A/S

                                            By  Lee Remmers
                                            Add to cart
                                            The Lundbeck case study describes the initial public offering (IPO) that the company made in the summer of 1999.
                                              View case

                                              Glaxo Italia S.P.A.: The Zinnat Marketing Decision

                                              By  Robert Bruner
                                              Add to cart Free Case award
                                              In September 1990, the financial controller of the Italian subsidiary of Glaxo must evaluate a financial analysis comparing two marketing strategies for introducing a new antibiotic into the Italian market. The task for the student is to evaluate and correct the discounted cash flow analysis.

                                                Published 01 Jan 1992

                                                Reference 4386

                                                Length 21 page(s)

                                                Topic Economics & Finance

                                                Region Europe

                                                Industry Pharmaceuticals

                                                View case

                                                Glaxo Italia S.P.A.: The Zinnat Marketing Decision

                                                By  Robert Bruner
                                                Add to cart Free Case award
                                                In September 1990, the financial controller of the Italian subsidiary of Glaxo must evaluate a financial analysis comparing two marketing strategies for introducing a new antibiotic into the Italian market. The task for the student is to evaluate and correct the discounted cash flow analysis.
                                                  View case